This is a pilot study in 40 subjects with definite ALS to evaluate the efficacy of valproate
and lithium carbonate. After a random assignation of the dual treatment vs. placebo, a
follow-up of 20 months will allow to know the clinical and functional evolution so as the
status of biomarkers under each treatment.
Phase:
Phase 2
Details
Lead Sponsor:
El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez